Galapagos

Galapagos is a pioneering biotechnology company, developing innovative medicines that will improve people’s lives. Our unique target discovery platform is transforming how medicines are discovered. A no fear of failure culture fuels our ambition to explore uncharted territory. At Galapagos, we are relentless in our drive to search for medicines with new modes of action that address high unmet patient needs. We focus on developing medicines which change the course of the disease, rather than just treat the symptoms. That is our promise to patients. Today our pipeline ranges from inflammation to fibrosis candidate drugs. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 1000 employees working in Belgium, the Netherlands, France, Spain, Italy, Germany, the UK, Croatia, Switzerland and the USA.